Companies, authorities and scientists can save time, money and test animals in the risk assessment of nanomaterials by using available data.

The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.

Modifications to the National Immunisation Programme have led to fewer cases of whooping cough among children.

RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.

RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.

Nanotechnology offers improved options for the diagnosis and treatment of cancer.

In a new publication, RIVM indicates scientific challenges in the use of the EU definition for nanomaterial in legislation.

In recent years, an increasing number of applications and products containing or using nanomaterials have become available.